NYSE:PBHPrestige Consumer Healthcare Stock Price, Forecast & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PBH shares have increased by 13.0% and is now trading at $40.59. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Prestige Consumer Healthcare.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare Inc (NYSE:PBH) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.82 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.08. The firm had revenue of $251.20 million for the quarter, compared to the consensus estimate of $239.65 million. Prestige Consumer Healthcare had a return on equity of 13.33% and a net margin of 14.77%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.72 EPS. View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare issued an update on its first quarter earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of $0.70 or more for the period, compared to the Thomson Reuters consensus EPS estimate of $0.69. The company issued revenue guidance of ~$220 million or more, compared to the consensus revenue estimate of $232.21 million.

7 brokerages have issued 1-year price targets for Prestige Consumer Healthcare's stock. Their forecasts range from $43.00 to $91.00. On average, they expect Prestige Consumer Healthcare's share price to reach $71.00 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price. View analysts' price targets for Prestige Consumer Healthcare.

Media headlines about PBH stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prestige Consumer Healthcare earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutPrestige Consumer Healthcare.

Some companies that are related to Prestige Consumer Healthcare include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Inter Parfums (IPAR), Medifast (MED), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Gilead Sciences (GILD), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), Johnson & Johnson (JNJ), TG Therapeutics (TGTX), Flexion Therapeutics (FLXN), Marathon Petroleum (MPC), Pfizer (PFE), AT&T (T) and Thermo Fisher Scientific (TMO).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.66%), Champlain Investment Partners LLC (4.92%), Wells Fargo & Company MN (4.01%), JPMorgan Chase & Co. (3.82%), State Street Corp (3.55%) and Acadian Asset Management LLC (2.99%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett, Ronald M Lombardi and Timothy Connors. View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., BlackRock Inc., JPMorgan Chase & Co., First Manhattan Co., Invesco Ltd., Massachusetts Financial Services Co. MA, The Manufacturers Life Insurance Company , and Morgan Stanley. View insider buying and selling activity for Prestige Consumer Healthcare.

PBH stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, Grantham Mayo Van Otterloo & Co. LLC, Monarch Partners Asset Management LLC, Champlain Investment Partners LLC, Jennison Associates LLC, Acadian Asset Management LLC, and Citigroup Inc.. View insider buying and selling activity for Prestige Consumer Healthcare.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $40.59.

Prestige Consumer Healthcare has a market capitalization of $2.03 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 530 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]